GlassScriptPhysician profile
Ronald N Duncan
NPI 1629090980
$5,785.55
in general payments reported to CMS, 2019-2025
31 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $199 · 2022: $607 · 2023: $1,106 · 2024: $1,556 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956 · Education: $35.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.22 |
| Education | $35.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $872.59 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $756.81 | 2022-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $635.00 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $500.46 | 2022-2025 | |
| Lilly USA, LLC | $445.77 | 2019-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $345.27 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $315.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.82 | 2019-2025 | Jardiance |
| Amgen INC. | $198.68 | 2019-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $169.22 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $153.70 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $152.99 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $116.53 | 2019-2024 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.76 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $95.66 | 2023 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.24 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $91.70 | 2022-2024 | Eliquis |
| Axsome Therapeutics, INC. | $82.76 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $66.12 | 2019-2022 | |
| Corcept Therapeutics | $56.19 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.63 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $49.45 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $44.70 | 2023-2024 | Rexulti |
| Lundbeck LLC | $34.58 | 2024 | Rexulti |
| Ascensia Diabetes Care US INC. | $31.57 | 2025 | |
| Verona Pharma, INC. | $18.17 | 2025 | Ohtuvayre |
| Sanofi Pasteur INC. | $15.70 | 2019 | |
| Amarin Pharma, INC. | $14.13 | 2019 | |
| Merck Sharp & Dohme LLC | $11.09 | 2020 | |
| Phathom Pharmaceuticals, INC. | $8.00 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.